Your browser doesn't support javascript.
loading
Immunohistochemical biomarkers are prognostic relevant in addition to the ESMO-ESGO-ESTRO risk classification in endometrial cancer.
Vrede, S W; van Weelden, W J; Visser, N C M; Bulten, J; van der Putten, L J M; van de Vijver, K; Santacana, M; Colas, E; Gil-Moreno, A; Moiola, C P; Mancebo, G; Krakstad, C; Trovik, J; Haldorsen, I S; Huvila, J; Koskas, M; Weinberger, V; Bednarikova, M; Hausnerova, J; van der Wurff, A A; Matias-Guiu, X; Amant, F; Snijders, M P L M; Küsters-Vandevelde, H V N; Reijnen, C; Pijnenborg, J M A.
Afiliação
  • Vrede SW; Department of Obstetrics and Gynaecology, Radboud university medical center, Nijmegen, the Netherlands; Department of Obstetrics and Gynaecology, Canisius-Wilhelmina Hospital, Nijmegen, the Netherlands. Electronic address: stephanie.vrede@radboudumc.nl.
  • van Weelden WJ; Department of Obstetrics and Gynaecology, Radboud university medical center, Nijmegen, the Netherlands.
  • Visser NCM; Department of Pathology, Stichting PAMM, Eindhoven, the Netherlands; Department of Pathology, Radboud university medical center, Nijmegen, the Netherlands.
  • Bulten J; Department of Pathology, Radboud university medical center, Nijmegen, the Netherlands.
  • van der Putten LJM; Department of Obstetrics and Gynaecology, Radboud university medical center, Nijmegen, the Netherlands.
  • van de Vijver K; Department of Pathology, Ghent University Hospital, Cancer Research Institute Ghent (CRIG), Ghent, Belgium.
  • Santacana M; Department of Pathology and Molecular Genetics and Research Laboratory, Hospital Universitari Arnau de Vilanova, University of Lleida, IRBLleida, CIBERONC, Lleida, Spain.
  • Colas E; Biomedical Research Group in Gynaecology, Vall Hebron Institute of Research, Universitat Autònoma de Barcelona, CIBERONC, Barcelona, Spain.
  • Gil-Moreno A; Gynecological Department, Vall Hebron University Hospital, CIBERONC, Barcelona, Spain; Pathology Department, Vall Hebron University Hospital, CIBERONC, Barcelona, Spain.
  • Moiola CP; Biomedical Research Group in Gynaecology, Vall Hebron Institute of Research, Universitat Autònoma de Barcelona, CIBERONC, Barcelona, Spain.
  • Mancebo G; Department of Obstetrics and Gynaecology, Hospital del Mar, PSMAR, Barcelona, Spain.
  • Krakstad C; Department of Obstetrics and Gynaecology, Haukeland University Hospital, Bergen, Norway; Centre for Cancer Biomarkers, Department of Clinical Science, University of Bergen, Bergen, Norway.
  • Trovik J; Department of Obstetrics and Gynaecology, Haukeland University Hospital, Bergen, Norway.
  • Haldorsen IS; Centre for Cancer Biomarkers, Department of Clinical Science, University of Bergen, Bergen, Norway; Mohn Medical Imaging and Visualization Centre, Department of Radiology, Haukeland University Hospital, Bergen, Norway.
  • Huvila J; Department of Pathology, University of Turku, Turku, Finland.
  • Koskas M; Department of Obstetrics and Gynaecology Department, Bichat-Claude Bernard Hospital, Paris, France.
  • Weinberger V; Department of Obstetrics and Gynaecology, University Hospital in Brno and Masaryk University, Brno, Czech Republic.
  • Bednarikova M; Department of Internal Medicine, Hematology and Oncology, University Hospital in Brno and Masaryk University, Brno, Czech Republic.
  • Hausnerova J; Department of Pathology, University Hospital in Brno and Masaryk University, Brno, Czech Republic.
  • van der Wurff AA; Department of Pathology, Elisabeth-TweeSteden Hospital, Tilburg, the Netherlands.
  • Matias-Guiu X; Department of Pathology and Molecular Genetics and Research Laboratory, Hospital Universitari Arnau de Vilanova, University of Lleida, IRBLleida, CIBERONC, Lleida, Spain.
  • Amant F; Department of Oncology, KU Leuven, Leuven, Belgium; Department of Gynaecologic Oncology, Netherlands Cancer Institute and Amsterdam Medical Centers, Amsterdam, the Netherlands.
  • Snijders MPLM; Department of Obstetrics and Gynaecology, Canisius-Wilhelmina Hospital, Nijmegen, the Netherlands.
  • Küsters-Vandevelde HVN; Department of Pathology, Canisius-Wilhelmina Hospital, Nijmegen, the Netherlands.
  • Reijnen C; Department of Radiation Oncology, Radboud university medical center, Nijmegen, the Netherlands.
  • Pijnenborg JMA; Department of Obstetrics and Gynaecology, Radboud university medical center, Nijmegen, the Netherlands.
Gynecol Oncol ; 161(3): 787-794, 2021 06.
Article em En | MEDLINE | ID: mdl-33858677
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias do Endométrio / Molécula L1 de Adesão de Célula Nervosa Tipo de estudo: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Female / Humans País/Região como assunto: Europa Idioma: En Revista: Gynecol Oncol Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias do Endométrio / Molécula L1 de Adesão de Célula Nervosa Tipo de estudo: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Female / Humans País/Região como assunto: Europa Idioma: En Revista: Gynecol Oncol Ano de publicação: 2021 Tipo de documento: Article